Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute

MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose pr...

Related Keywords

Portland ,Oregon ,United States ,Bridge View ,Robertw Franz ,Robert Bitterman ,Brendan Curti ,Caitlin Kontulis ,Michael Adams ,Judith Ann Hartmann ,Andrew Weinberg ,Earlea Chiles Research Institute ,Nasdaq ,Laboratory Of Basic Immunology ,Joseph Health ,Clinical Research ,Agonox Inc ,Providence Cancer Institute Of Oregon ,Providence Cancer Institute In Portland ,Phio Pharmaceuticals Corp ,Phio Pharmaceuticals ,Providence Cancer Institute ,Adoptive Cell Therapy ,Principal Investigator Brendan Curti ,Endowed Chair ,Research Institute ,Judith Ann Hartmann Endowed Chair ,Basic Immunology ,Cancer Institute ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,